
Health Care · NYSE: COR
Cencora earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends September · next results expected around 3 Feb 2027
Latest: Q4 FY2026
Cencora is reorganizing into two customer-focused segments and buying American Oncology Network, deepening its bet on specialty and oncology physician practices after closing OneOncology.
Cencora closed its OneOncology acquisition in February 2026, adding a physician-practice platform that lifted U.S. profitability. Specialty product sales to health systems and physician practices grew, as did GLP-1 sales, which carry lower margins. Brand manufacturer price declines and lower sales to its large mail order customer partly offset growth. It also sold U.S. Consulting Services in April 2026.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 FY24 | $79.1B * |
| Q1 FY25 | $81.5B |
| Q2 FY25 | $75.5B |
| Q3 FY25 | $80.7B |
| Q4 FY25 | $83.7B * |
| Q1 FY26 | $85.9B |
| Q2 FY26 | $78.4B |
| Q3 FY26 | $84.8B |
Data
| Q1 FY25 | $2.50 |
| Q2 FY25 | $3.68 |
| Q3 FY25 | $3.52 |
| Q1 FY26 | $2.87 |
| Q2 FY26 | $8.40 |
| Q3 FY26 | $3.94 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 FY24 | 0.2% |
| Q1 FY25 | 0.9% |
| Q2 FY25 | 1.4% |
| Q3 FY25 | 1.1% |
| Q4 FY25 | 0.0% |
| Q1 FY26 | 0.9% |
| Q2 FY26 | 1.5% |
| Q3 FY26 | 1.3% |
Data
| Q4 FY24 | $818.1M |
| Q1 FY25 | -$2.8B |
| Q2 FY25 | $3.2B |
| Q3 FY25 | -$74.0M |
| Q4 FY25 | $2.9B |
| Q1 FY26 | -$2.4B |
| Q2 FY26 | $1.2B |
| Q3 FY26 | $2.4B |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $79.1Bd | $81.5B | $75.5B | $80.7B | $83.7Bd | $85.9B | $78.4B | $84.8B |
| Gross margin | 3.2% | 3.1% | 4.1% | 3.6% | 3.5% | 3.6% | 4.6% | 4.3% |
| Operating income | $126.6Md | $706.3M | $1.0B | $867.7M | $18.5Md | $760.4M | $1.1B | $1.1B |
| Operating margin | 0.2% | 0.9% | 1.4% | 1.1% | 0.0% | 0.9% | 1.5% | 1.3% |
| Net income | $3.4Md | $488.6M | $717.9M | $687.4M | -$339.7Md | $559.6M | $1.6B | $763.5M |
| Diluted EPS | — | $2.50 | $3.68 | $3.52 | — | $2.87 | $8.40 | $3.94 |
| Operating cash flow | $1.0Bd | -$2.7B | $3.4Bd | $109.2Md | $3.1Bd | -$2.3B | $1.3Bd | $2.7Bd |
| Capital expenditure | $182.3Md | $105.9M | $129.1Md | $183.2Md | $249.8Md | $119.4M | $165.6Md | $226.0Md |
| Free cash flow | $818.1M | -$2.8B | $3.2B | -$74.0M | $2.9B | -$2.4B | $1.2B | $2.4B |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 5 Aug 202610-Q for the period ended 30 Jun 2026SEC ↗
- 6 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 4 Feb 202610-Q for the period ended 31 Dec 2025SEC ↗
- 25 Nov 202510-K for the period ended 30 Sep 2025SEC ↗
- 6 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 7 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 5 Feb 202510-Q for the period ended 31 Dec 2024SEC ↗
- 26 Nov 202410-K for the period ended 30 Sep 2024SEC ↗